{"classes":[{"categories":[{"measurements":[{"comment":"Here, \"NA\" signifies that lower limit of full range could not be estimated as it was below the quantification limit.","groupId":"OG000","lowerLimit":"NA","upperLimit":"7.65","value":"2.25"},{"comment":"Here, \"NA\" signifies that lower limit of full range could not be estimated as it was below the quantification limit.","groupId":"OG001","lowerLimit":"NA","upperLimit":"10.40","value":"2.01"},{"comment":"Here, \"NA\" signifies that lower limit of full range could not be estimated as it was below the quantification limit.","groupId":"OG002","lowerLimit":"NA","upperLimit":"23.0","value":"5.61"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"title":"Day 352"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.31","upperLimit":"14.7","value":"6.70"},{"groupId":"OG001","lowerLimit":"3.21","upperLimit":"11.90","value":"7.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Day 1024"}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"description":"Mean concentration of soluble BCMA levels in serum after single infusion of JNJ-68284528 were reported.","dispersionType":"Full Range","groups":[{"description":"Participants received a conditioning regimen of cyclophosphamide 300 milligrams per meter square (mg/m\\^2) intravenous (IV) infusion and fludarabine 30 mg/m\\^2 as IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received target dose of JNJ-68284528 0.75\\*10\\^6 chimeric antigen receptor T (CAR-T) cells per kilogram (cells/kg) (range: 0.5-1.0\\*10\\^6 CAR-positive viable cells/kg) as IV infusion.","id":"OG000","title":"Phase 1b (US Population)"},{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received recommended phase 2 dose (RP2D) dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"OG001","title":"Phase 2 (US Population)"},{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received RP2D dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"OG002","title":"Phase 2 (Japan Population)"}],"paramType":"MEAN","populationDescription":"mITT analysis set included all participants who received a JNJ-68284528 infusion at the targeted RP2D dose level. Here, N (number of participants analyzed) signifies participants who were evaluable for this outcome measure. Zero (0) participants in the number analyzed field for arm \"Phase 2 (Japan Population)\" at Day 1024 signifies that no participants were available for the analysis because no sBCMA samples were collected and analyzed due to change in planned analysis.","reportingStatus":"POSTED","timeFrame":"Days 352 and 1024","title":"Phase 1b and Phase 2: Mean Concentration of Soluble B-cell Maturation Antigen (BCMA) Levels in Serum After Single Infusion of JNJ-68284528","type":"SECONDARY","unitOfMeasure":"Micrograms per liter (mcg/L)"}